Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06923124 · ClinicalTrials.gov registry record
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
A clinical trial of Familial Mediterranean Fever, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 44
- Enrollment target
- 1
- Study location
NCT06923124: Completed study of Familial Mediterranean Fever, sponsored by Novartis Pharmaceuticals.
NCT06923124 is a study of Familial Mediterranean Fever that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06923124, a study of Familial Mediterranean Fever, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.
Primary Outcome
Clinical characteristic categories included: * Diagnostic criteria of FMF (symptom associated with FMF, without a proven infectious cause, with a recurrent pattern and/or accompanied by a genetic test suggestive of Mediterranean FeVer gene \[MEFV\]) * Family history of FMF * MEFV genotypes * Phenotypes of interleukin-1 (IL-1) mediated autoinflammatory disease * Diagnosis prior to FMF
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2024-05-28 |
What the finished NCT06923124 record still lists
NCT06923124 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 1 condition, with Familial Mediterranean Fever appearing as the primary indexed condition, and to 0 interventions.
NCT06923124 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06923124 about?
NCT06923124 is a clinical study titled "A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life". A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was coll...
What is the current status of trial NCT06923124?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2023-03-30. Estimated completion is 2024-05-28.
What conditions does trial NCT06923124 study?
This clinical trial studies the following conditions: Familial Mediterranean Fever.
Who is sponsoring clinical trial NCT06923124?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06923124 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Mediterranean Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI